The Sabin-Aspen Vaccine Science & Policy Group convened in 2018 to explore challenges and opportunities to develop a universal influenza vaccine. The group’s recommendations on how to [...]
“JERUSALEM, April 22, 2019 /PRNewswire/ — BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), announced today that the Management Committee of the European Investment Bank (EIB) agreed to [...]
“The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in [...]
“Work to develop a universal flu vaccine using a microneedle patch will continue at Georgia State University’s Institute for Biomedical Sciences with a $3.86 million grant from the National [...]
“Sen. Edward J. Markey (D-MA) and Rep. Rosa DeLauro (D-CT) recently reintroduced a measure designed to bolster the financial support for a universal influenza vaccine protecting against [...]
“FluGen, Inc. today announced preliminary data from a human challenge trial with its investigational intranasal M2SR vaccine showing, for the first time, protection against a highly [...]
The 2nd Annual meeting of the Consortium took place November 7-8 in Atlanta, GA, USA. The full meeting report is posted here.
Site by ClockworkWD - Atlanta SEO Company
